Related Experiment Video
Updated: Apr 27, 2026

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
Published on: July 31, 2021
Vaccination coverage for infants: cross-sectional studies in two regions of Belgium
Emmanuelle Robert1, Michèle Dramaix2, Béatrice Swennen1
1Research Center of Health Policy and Systems-International Health, School of Public Health, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Insights
Infant vaccination coverage in Belgium is high, with nearly all children receiving initial doses. Maternal and child clinic attendance significantly impacts vaccine uptake, though education level does not. Efforts are needed to boost coverage for certain vaccine doses.
Area of Science:
- Pediatrics
- Public Health
- Epidemiology
Background:
- Infant vaccination is crucial for disease prevention.
- Assessing vaccination coverage is essential for public health planning.
- Understanding factors influencing vaccine uptake aids in targeted interventions.
Purpose of the Study:
- To estimate infant vaccination coverage in Wallonia and the Brussels-Capital Region in 2012.
- To identify factors associated with infant vaccination uptake.
- To evaluate the need for improved vaccination strategies.
Main Methods:
- Cross-sectional studies conducted in 2012.
- Face-to-face questionnaires administered by trained investigators.
- Retrospective evaluation of vaccination status in 18- to 24-month-old children.
Main Results:
- High coverage for the first dose of inactivated poliovirus vaccine-diphtheria-tetanus-pertussis (IPV-DTaP) (approx. 99%) and pneumococcal vaccine (approx. 97%).
- Coverage for the fourth dose of IPV-DTaP (90%) and MMR vaccine (94%) was also high.
- Attendance at maternal and child clinics (MCH) was the most significant factor associated with vaccination coverage.
Conclusions:
- While overall infant vaccination coverage is high, specific doses require improvement, particularly the fourth dose of hexavalent vaccine (DTaP-IPV-HBV/Hib).
- Increased efforts are needed to reach herd immunity thresholds for Haemophilus influenzae type b (Hib) and pertussis.
- Maternal and child clinic attendance is a key factor in successful infant immunization programs.
Methods And Objectives:
To estimate infant vaccination coverage in the French-speaking region of Belgium (Wallonia) and in the Brussels-Capital Region, two cross-sectional studies were performed in 2012. A face-to-face questionnaire was administered by trained investigators. The objective was to evaluate infant vaccination coverage retrospectively in 18- to 24-month-old children. These studies offered the opportunity to assess some factors influencing vaccine uptake in infants.
Results And Discussion:
Approximately 99% of the children had received the first dose of IPV-DTaP, 90% the fourth dose, 94% the MMR vaccine, 97% the first dose of pneumococcal vaccine, and 90% the third dose. In both regions, when fitting a logistic model, the most associated factor was attendance at maternal and child clinics (MCH). No association was observed between vaccination coverage and the mother's level of education. For the last immunization session, where the mother was a Belgian native and when she worked more hours, child was better immunized, but only in Brussels.
Conclusion:
Coverage for the fourth dose of hexavalent vaccine (DTaP-IPV-HBV/Hib) needs to be increased. Indeed, additional effort is needed to increase HIB and pertussis coverage rates because the herd immunity threshold for these two diseases has not been reached.
More Related Videos
Related Concept Videos
Vaccinations
Vaccines
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Bias in Epidemiological Studies
Cross-reactivity
Microorganisms in Medicine and Therapeutics

